Hormone replacement therapy and endometrial cancer in Ontario, Canada.

https://arctichealth.org/en/permalink/ahliterature198768
Source
J Clin Epidemiol. 2000 Apr;53(4):385-91
Publication Type
Article
Date
Apr-2000
Author
M G Jain
T E Rohan
G R Howe
Author Affiliation
Department of Public Health Sciences, University of Toronto, 308-12 Queen's Park Crescent West, Toronto, Ontario, Canada. meera.jain@utoronto.ca
Source
J Clin Epidemiol. 2000 Apr;53(4):385-91
Date
Apr-2000
Language
English
Publication Type
Article
Keywords
Adult
Aged
Case-Control Studies
Confidence Intervals
Endometrial Neoplasms - chemically induced - epidemiology - pathology
Female
Hormone Replacement Therapy - adverse effects - statistics & numerical data
Humans
Interviews as Topic - methods
Logistic Models
Middle Aged
Neoplasm Staging
Odds Ratio
Ontario - epidemiology
Questionnaires
Risk factors
Abstract
Estrogen therapy reduces the risk of osteoporosis and cardiovascular diseases but is associated with an increased risk of endometrial cancer. We have assessed the impact of a regimen of estrogen with progestogen on risk of endometrial cancer for women 48 years and older. We conducted a case-control study in Ontario, Canada, from 1994 to 1998 by interviewing registry-based cases (n = 512) and population controls (n = 513) to obtain information on use of hormones and dietary habits. Compared to non-users, the use of opposed hormone therapy in sequential regimen for more than three years showed a borderline increase in risk (OR = 1.49, 95% CI 0.93-2. 40), but this increase was much less than among women on unopposed estrogen (OR = 4.12, 95% CI 2.21-7.71). Stronger associations were observed when duration of sequential hormone use was examined as a continuous variable (OR per three years of use = 1.21, 95% CI 1.03-1. 42). The effect of opposed hormone therapy on endometrial cancer risk appears to vary both by usage patterns and by patient characteristics of body weight and history of diabetes.
PubMed ID
10785569 View in PubMed
Less detail